Rallybio Corp (RLYB) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Rallybio Corp is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. The company's two most advanced programs are RLYB212 (anti-HPA-1a antibody for fetal and neonatal alloimmune thrombocytopenia) and RLYB116 (C5 inhibitor for complement dysregulation). Both programs have completed Phase 1 studies. The company plans to initiate a Phase 2 clinical trial for RLYB212 in the fourth quarter of 2024.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $299 | $0 | $299 | $0 |
| Net Loss | $(16,236) | $(18,630) | $(35,265) | $(35,948) |
| Loss Per Share (Basic/Diluted) | $(0.37) | $(0.46) | $(0.83) | $(0.89) |
| Operating Expenses | $17,334 | $20,083 | $37,121 | $38,457 |
| Cash & Cash Equivalents | $16,671 | $32,559 | $16,671 | $32,559 |
| Marketable Securities | $71,943 | $85,435 | $71,943 | $85,435 |
| Total Liquidity (Cash + Securities) | $88,614 | $117,994 | $88,614 | $117,994 |
Note: Revenue consists entirely of collaboration and license revenue. The company has no commercial product sales.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $0.3 million in revenue for Q2 2024, compared to zero in Q2 2023. This stems from a new Collaboration Agreement with Johnson & Johnson (J&J) and the allocation of consideration from a concurrent equity investment by J&J Innovation (JJDC).
- Cost Reductions: Operating expenses decreased by approximately $2.7 million in Q2 2024 compared to Q2 2023. This reduction is primarily attributed to a workforce reduction of approximately 45% announced in February 2024, which resulted in $3.3 million in restructuring charges (recognized in Q1 2024) and lower ongoing personnel costs.
- Financing Activity: In April 2024, the company sold 3.6 million shares of common stock to JJDC for gross proceeds of approximately $6.6 million. This transaction was combined with the collaboration agreement.
- Liquidity: Total cash, cash equivalents, and marketable securities decreased from $118.0 million at year-end 2023 to $88.6 million as of June 30, 2024, due to operating cash burn and investment in joint ventures.
Guidance, Outlook, and Risks
- Outlook: Management expects current liquidity ($88.6 million) to fund operations into the middle of 2026. The company anticipates continuing to incur significant losses as it advances clinical development.
- Development Milestones:
- RLYB212: Phase 2 dose confirmation trial initiation planned for Q4 2024. A natural history study has screened over 12,000 pregnant women as of August 1, 2024.
- RLYB116: Manufacturing enhancements are on track for completion in Q3 2024. The company plans to provide an update on future plans later in 2024.
- RLYB332: Nonclinical data presentation anticipated in Q4 2024.
- Risks:
- Capital Needs: The company will require substantial additional capital to complete development and commercialization. Failure to secure financing could force delays or termination of programs.
- Regulatory Uncertainty: Success depends on obtaining regulatory approval for RLYB212 and RLYB116, which are in early-stage clinical development. There is no guarantee of approval.
- Competition: RLYB116 faces competition from established therapies (e.g., Soliris, Ultomiris) for PNH and gMG.
Investor Verification Checklist
- Liquidity Runway: Verify the accuracy of the "middle of 2026" cash runway estimate given the current burn rate and potential for increased clinical costs.
- Restructuring Impact: Confirm that the 45% workforce reduction has stabilized operating expenses and that no further significant restructuring charges are anticipated.
- RLYB212 Trial Initiation: Monitor the timeline for the Phase 2 trial initiation in Q4 2024 and the transition of European sites from the natural history study to the Phase 2 trial.
- Collaboration Revenue: Review the terms of the J&J Collaboration Agreement to understand the timing and conditions for the remaining potential revenue (up to $0.7 million in enrollment milestones).
- Joint Venture Exposure: Assess the financial impact of the loss on the investment in the Exscientia joint venture (RE Ventures I, LLC), which recorded a loss of $1.2 million YTD 2024.